Arcutis Biotherapeutics Inc. (ARQT) News

Arcutis Biotherapeutics Inc. (ARQT): $8.63

0.71 (-7.60%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ARQT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#96 of 351

in industry

Filter ARQT News Items

ARQT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARQT News Highlights

  • For ARQT, its 30 day story count is now at 8.
  • Over the past 13 days, the trend for ARQT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ARQT are AMP, LI and DRUG.

Latest ARQT News From Around the Web

Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 28, 2023

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Yahoo | December 27, 2023

11 High Growth Micro-Cap Stocks to Buy

In this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […]

Yahoo | December 24, 2023

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Yahoo | December 19, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!

William White on InvestorPlace | December 18, 2023

Arcutis shares jump after FDA approves drug for chronic skin condition

Investing.com -- Shares in Arcutis Biotherapeutics (NASDAQ:ARQT) surged on Monday after the U.S. Food and Drug Administration approved the use of the drugmaker's treatment for a skin condition called seborrheic dermatitis in patients nine years of age or older.

Yahoo | December 18, 2023

Arcutis shares rally in after-hours trading on FDA approval

More on Arcutis Biotherapeutics

UPDATE 3-US FDA approves Arcutis' drug to treat chronic skin disease

The U.S. Food and Drug Administration (FDA) on Friday approved Arcutis Biotherapeutics' drug for treating a skin condition called seborrheic dermatitis in individuals nine years of age and older. The health regulator's nod makes roflumilast foam the first topical drug for treating moderate to severe seborrheic dermatitis with a new mechanism of action in over two decades, according to the company. Seborrheic dermatitis, a common, chronic and recurrent inflammatory skin disease, affects more than 10 million people in the U.S., Arcutis said.

Yahoo | December 15, 2023

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of useZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic dermatitisFirst drug approved for seborrheic dermatitis with a new mechanism of action in over two decadesSeborrheic dermatitis affects more than 10 million people i

Yahoo | December 15, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 shares of Arcutis’ common stock to 7 newly hired employees. These awards were approved by the Compensation Committee of

Yahoo | December 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!